EuroHear - Bringing The Genetic Basis Of Deafness To Light - An Interview With Jacques Remacle, Scientific Officer European Commission
- Monday, January 8, 2007, 14:47
- Ear, Nose and Throat, Hearing / Deafness
- 6 views
- Add a comment
Why is research on hearing impairment a priority for the European Commission?
“Hearing impairment (HI) is a real heath problem in Europe. In Europe, 40 million individuals (over 10 % of its population) suffer from HI with 2 million profoundly deaf. In children, deafness impedes language acquisition and generates learning difficulties.
In adults, if often leads to severe disruption of social links which very frequently results in depression. All together, in Europe, the financial cost of HI has been estimated at 3,500 Euros per year per patient and includes special education, speech therapy, hearing aids, and physician and specialists fees. In the range of 100 billion Euros, this is more than the combined economic cost of epilepsy, multiple sclerosis, spinal injury, stroke and Parkinson’s disease.
Furthermore, this figure is likely to grow continuously in time due to noise pollution and ageing. Hearing loss is the third leading chronic disability following arthritis and hypertension. Therefore, Europe supports research to find new solutions to alleviate HI and thereby decreasing the burdens of these defects on European Society.”
What does Europe expect from EuroHear in terms of scientific results and benefits to society?
“EuroHear is an integrated, multidisciplinary project including 25 different research teams throughout Europe that share the same interest in gaining new knowledge on the hearing processes. Research is focused on the critical step in which sound waves in the inner ear are transformed into electrical signals and sent to the brain.
Progress will strongly depend on the close interaction between human geneticists who will identify the susceptibility genes for HI, animal geneticists who will test the function of these genes in animal models, physiologists, who will dissect the functions of the genes in vitro.
The knowledge gained from this project will contribute to the development of better diagnostic tools for the genetic factors causing HI and open new avenues and future therapies. Therefore, EuroHear is an ambitious pan-European effort for which the benefits for society will be considerable in the longer term.”
Experience shows that the interval between scientific discovery and translation to tangible benefits can be long and certainly longer that many funding periods. In the light of the experience of other projects, what steps do you think EuroHear should be emphasizing to encourage translational research?
“EuroHear is mainly a research project aiming at deciphering the auditory processes. However, we should not forget that patients are waiting for solutions to help them now. They are not interested in publications in top scientific journals. Translating knowledge into new benefits for HI patient must be a priority for the future in order to gather further investment in this research area. Nevertheless, efficient translation depends on the level and quality of the knowledge that we have on biological processes.
The more detailed our knowledge on the hearing process and on HI, the better our chances of finding efficient solutions for treating HI patients. However, building knowledge is not enough to catalyze the translation process and efforts should be made to disseminate any advances to the industry by e.g. creating a discussion platform between EuroHear and the industry. With 10% of the population affected by HI, the demand for new HI therapies is substantial and the market will surely be attractive for the industry.”
EuroHear is 12.5 million Euro grant from the Life Science Programme. How is it positioned among Integrated Project support, is it a big project from your prospective?
“In terms of budget (12.5 million Euros), EuroHear is amongst the largest integrated projects funded under FP6 LifeScience Priority. One of the largest networks for an integrated project as well.
EuroHear is indeed a challenging project. As substantially supported by the European Commission and led by renowned scientific leaders, it is realistic to think that all the objectives will be met by the conclusion of the project. However, strong interaction and collaboration between all the project’s partners is key for its success.
Indeed, all the partners should join forces to build up coherent strategies to address the difficulties encountered and avoid duplication. A strong European integrated and multidisciplinary network is important for hearing science. By investing 12.5 million Euros in EuroHear, the EU Commission has understood the potential of this research in Europe and we all hope, HI sufferers included, that this project will deliver as promised.”
Many of the enabling technologies in EuroHear come from a wide range of different disciplines. How does the Life Sciences Programme intend to ensure that such multidisciplinary approaches continue to be encouraged?
“In terms of instruments and strategies, the FP7 will not be different than FP6. The EU Commission will continue supporting projects with ambitious objectives that can only be achieved by European networks involving multidisciplinary expertises.
Nevertheless, translational research is stressed in FP7. Therefore, to be well positioned for a future FP7 project, providing strategies that translate results into new potential solutions for the HI will be a deciding factor. All dimensions of current FP6 projects will be taken into account: scientific excellence, integration and networking and bringing application to market.”
EuroHear has a significant training component amongst its activities. How would you judge the success of this component in the medium and long term? “Continuing training is an important aspect of every scientific career. We want a new generation of scientists in the field of auditory sciences to be trained. These days, multidisciplinary skills are important assets for a scientist. I think that the partners of the EuroHear network should use the training and resource opportunities to train their students in different disciplines such as human and mouse genetics, electrophysiology, viral gene delivery systems, yeast two hybrid and so on.
Training can also take different forms. It can be a theoretical course, a practical course or a student exchange between different partners. To assess the quality of the training, we consider feedback from the trainees and how their comments are taken into account. The level of exchange, number students, and length of training periods is also a very good indicator. In the long term, the successful careers of the young investigators who have been trained via the EuroHear project will sign the true success of the training programmes.
Nevertheless, I do appreciate that it will take several years before seeing the real benefit of the multidisciplinary training.”
What is your vision in the development and support of this area of research in FP7?
“The European Commission has been supporting research on deafness through successive FPs. So far these projects have been very successful and in particular, the FP5 project “hereditary deafness” coordinated by Prof. Christine Petit (Pasteur Institute, Paris, France) produced substantial progress in the understanding of the hearing process and in the identification of the genetic determinants of deafness. The current EuroHear consortium contains leading European researchers who have identified half of the 41 genes known to be associated with deafness. This indicates the competitiveness of European research in this field.
As mentioned above, HI is a societal and health problem. In FP7, currently being finalized, research on sensory defects is clearly indicated as a priority. There will be possibilities to submit a new research project on HI in FP7 but with more emphasis on the translational approach. Success of ongoing FP6 projects in all dimensions will be key for any further EC support. As already stressed, integration and enabling translation into application are gaining a steadily growing emphasis.”
Jacques Remacle Bio
Jacques Remacle’s work as a Scientific Officer at the European Commission involves the organisation of peer-review evaluations and follow-up of research projects that develop and apply functional genomics tools to the study of basic biological processes. His portfolio of projects includes the Integrated Project “EuroHear”.
About EuroHear
Bringing the genetic basis of Deafness to Light is a five-year scientific project started in December 2004 and supported by the priority “Life Sciences, genomics and biotechnology for health” within the Sixth Research Framework Programme of the European Commission.
There are 22.5 million hearing impaired people in Europe alone: hearing loss represents a handicap which can adversely affect a child’s educational performance and cognitive development, while presbycusis is the most common sensory deficit in the elderly. The handicap has a severe effect on the individual and those around him or her, as it becomes a major impediment to daily communication.
EuroHear has two closely inter-related objectives: to provide fundamental knowledge about the development and function of the inner ear, and to identify the molecular defects underlying hereditary hearing impairments (HI), including presbycusis, one of the most frequent forms of HI. Achieving these objectives will facilitate the development of therapies for alleviating HI.EuroHear is one of 4 important medical research projects taking place in Europe and part of APPEAR.
About the Author
Write a Comment
Gravatars are small images that can show your personality. You can get your gravatar for free today!
You must be logged in to post a comment.